Patient: Page 7
-
Reata’s stock plummets amid sudden FDA neuro office shakeup
The FDA’s longtime neuroscience head Billy Dunn stepped down, leaving industry reeling over how the agency’s new acting director could handle upcoming approval decisions.
By Karissa Waddick • Feb. 28, 2023 -
Q&A
Why patient care is a public affair
The VP of public affairs at Kyowa Kirin discusses her role in advocating for advocacy.
By Taren Grom • Feb. 23, 2023 -
Trendline
Artificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Q&A
Managing for resilience: Passage’s ups and downs in gene therapy
After a rocky year, Passage Bio’s CEO is focused on helping the rare disease specialist bounce back.
By Meagan Parrish • Feb. 15, 2023 -
Podcast
Woman of the Week: Bristol Myers Squibb’s Ester Banque
The 30-year veteran is heading up the “transformation” of one of the pharma giant’s most important therapeutic portfolios: hematology.
By Taren Grom • Feb. 15, 2023 -
Profile
For Complement’s CEO, storytelling could be just as critical as data
Dr. Rafiq Hasan has his sights on bringing lessons learned at Bayer to ophthalmology-focused Complement Therapeutics.
By Alexandra Pecci • Feb. 14, 2023 -
Why are there gaps in mental healthcare? Often it’s flawed trial methodology
Sunovion Pharmaceuticals has developed a more precise way to track symptoms that could be broadly adopted across the industry.
By Kelly Bilodeau • Feb. 10, 2023 -
Profile
United by inequity: The healthcare disparities plaguing rare disease patients and Black Americans
Guided by her personal experiences, Tamar Thompson is aiming to improve rare disease care through her advocacy work at Alexion, AstraZeneca Rare Disease.
By Alexandra Pecci • Feb. 7, 2023 -
Podcast
Woman of the Week: Bayer’s Dr. Yesmean Wahdan
The VP of medical affairs and women’s health is focused on an audacious goal to meet the needs of 100 million women globally.
By Taren Grom • Feb. 1, 2023 -
Patients are using social media — clinical trial experts can learn from that
Why an alliance of industry leaders is exploring the potential of social media as a treasure trove of real-world patient experience insights.
By Karissa Waddick • Jan. 30, 2023 -
Profile
A biotech CEO’s favorite ‘F’ word
At SFA Therapeutics, patients are the “focus” of Ira Spector’s approach to changing the course of autoimmune disease.
By Taren Grom • Jan. 26, 2023 -
Q&A
Gilead’s commercial chief on why 2023 will be a ‘coming out’ year
With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.
By Meagan Parrish • Jan. 26, 2023 -
Podcast
Woman of the Week: Dr. Lauren Lazar
As Calcium’s medical director, Lazar is leveraging next-generation innovation to create strategic connections between science and marketing for healthcare brands.
By Taren Grom • Jan. 25, 2023 -
Profile
Pro sports’ COVID protocols led to real-world data impacts for pharma
After years of pioneering new methods for using data and technology to improve patient health outcomes, IQVIA’s Christina Mack is on the cusp of a research revolution.
By Karissa Waddick • Jan. 16, 2023 -
Opinion
How biotechs can weather the market storm
Execs at JPM sound off on moves companies can make to survive the challenging market conditions.
By Meagan Parrish • Jan. 13, 2023 -
Profile
A new mission in menopause — extending the lives of women
Why Evernow CEO Alicia Jackson thinks menopause is the perfect inroad to helping women live longer lives.
By Meagan Parrish • Jan. 5, 2023 -
Nonprofits are bridging R&D’s valley of death
How charitable firms such as Advancium are helping to right the market wrongs of drug development.
By Kelly Bilodeau • Jan. 4, 2023 -
Opinion
The 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences
A preview of the top trends on the minds of industry and market leaders for the new year.
By Taren Grom • Jan. 3, 2023 -
Q&A
To drive trial diversity, one company is bringing them to the patient
For Lightship, increasing patient access to clinical trials is about meeting them where they are — literally.
By Karissa Waddick • Dec. 21, 2022 -
With mpox cases mysteriously dwindling, scientists search for answers
Was it a public health victory? Or did mpox ‘burn itself out?’ An epidemiologist weighs in.
By Kelly Bilodeau • Dec. 19, 2022 -
Podcast
Woman of the Week: Exelixis’ Dr. Vicki Goodman
With several blockbuster products under her belt, veteran oncologist and drug developer Dr. Vicki Goodman is looking to further evolve Exelixis’ pipeline to address hard-to-treat cancers.
By Taren Grom • Dec. 14, 2022 -
At the heart of hematology breakthroughs, a community of researchers and patients comes together
As new and advanced therapies are revealed at the annual meeting of the American Society of Hematology this week, the patients are always at the center.
By Michael Gibney • Dec. 13, 2022 -
Tracker
The 2023 PharmaVoice Year in Preview
Here’s a look at how industry leaders are navigating the key issues of 2023.
Dec. 12, 2022 -
The pharma giants making the biggest strides with global drug access
A recent report ranks the top 20 pharma companies by how well they’re boosting a critical component of health equity.
By Kelly Bilodeau • Dec. 12, 2022 -
Q&A
Takeda’s global quest for health equity
Takeda’s Center for Health Equity and Patient Affairs is built to address health inequality around the world and aims to raise the bar for the pharma industry.
By Taren Grom • Dec. 8, 2022 -
Q&A
Non-toxic and addiction free: The promise of a new pain med
Why South Rampart Pharma’s novel new molecule could be a key to solving the global pain epidemic.
By Taren Grom • Dec. 1, 2022